Indian pharmaceutical companies are sharpening their biosimilars strategy as the US Food and Drug Administration’s (FDA) proposed regulatory changes open a new window of opportunity in what is poised to become one of the most lucrative global markets. With the US biosimilars market expected to surge from $22.6 billion in 2025 to over $90 billion by 2034, Indian drugmakers are accelerating investments, partnerships, and potential acquisitions to secure an early advantage.

Regulatory Shift Unlocks Massive Opportunity

The transformational moment for the industry comes from the US FDA’s draft guidelines, which propose eliminating the requirement for comparative efficacy clinical trials—a step long regarded as the most expensive and time-consuming component of biosimilar development. Instead, the new framework would rely more heavily on advanced analytical and pharmacokinetic data to demonstrate similarity.

Industry experts note that the revised US FDA framework could reduce biosimilar development costs by nearly 50%, a significant shift for a segment that has traditionally required $100–200 million per molecule. Removing the need for comparative clinical efficacy trials dramatically lowers barriers to entry, enabling faster development timelines and making the US — the world’s largest biosimilars market — far more accessible for manufacturers. The regulatory change is widely viewed as a transformative moment that could accelerate market expansion and intensify global competition.

US Market Dynamics Favour Rapid Adoption

Although biosimilars currently represent just 5% of total US prescriptions, they make up more than 50% of overall drug spending—a striking imbalance that highlights the scale of opportunity for cost-effective alternatives. With US payers and pharmacy benefit managers actively pushing for biosimilar uptake to control rising healthcare costs, demand is expected to climb sharply over the next decade.

For Indian companies, this creates a high-growth opening where their established advantages—efficient manufacturing, competitive pricing, and robust development ecosystems—align perfectly with a streamlined approval pathway.

Indian Pharma Repositions: Expansion, M&A, and Portfolio Acceleration

Indian drugmakers are responding swiftly:

• Lupin aims to have its biosimilars portfolio contributing to US revenues by FY2027, with five launches planned by 2030, including Pegfilgrastim, Ranibizumab, and Eylea.
• Sun Pharma, traditionally focused on speciality products, is reassessing its biosimilars stance. The company noted that it is awaiting final FDA guidance before committing, acknowledging the twin effects of reduced investment needs and future strategic implications.
• Cipla has already made its entry with the launch of filgrastim in the US and plans to expand its presence in high-value biologic categories.

Acquisitions and licensing deals are becoming central to market-entry strategy. Indian firms are scouting for ready assets to shorten time-to-market and avoid heavy upfront R&D costs:

• Intas Pharmaceuticals acquired Udenyca, a pegfilgrastim biosimilar, from US-based Coherus for approximately $558 million, one of the largest biosimilar acquisitions by an Indian company.
• Cipla’s partnership with Tanvex BioPharma for filgrastim and Dr. Reddy’s Laboratories’ commercial collaboration with Alvotech for a denosumab biosimilar highlight the growing reliance on licensing to expand pipelines cost-efficiently.

R&D Investment Expected to Increase — With Faster Payback

Indian pharma companies currently allocate about 6–8% of revenues to R&D, with biosimilars historically representing only a small portion of that spend. The new regulatory climate could shift this significantly. Analysts anticipate that biosimilars could achieve return profiles similar to complex generics—a segment where Indian companies have already established global leadership.

It’s not just about cutting costs—it’s about accelerating timelines, scaling globally, and capturing a once-in-a-decade opportunity.

Also read: Tata 1mg–OneBanc Forge New Pathway to Cut India’s ₹30,000 Cr Corporate Health Burden

A Defining Moment for India’s Biologics Ambitions

With regulatory tailwinds, expanding market potential, and renewed strategic focus from major players, Indian pharma is well-positioned to emerge as a stronger competitor in the global biosimilars arena. As the US market enters a phase of unprecedented growth, Indian manufacturers appear poised to play a central role in shaping the next era of affordable, accessible biologic medicines.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!